Print this page    •   Back to Web version of article

U.S. News
U.S. Food and Drug Administration Approves Gilead's Once-Daily HIV Pill Complera

August 11, 2011

The Food and Drug Administration (FDA) on Wednesday approved the once-daily pill Complera for patients not previously treated for HIV.

Complera, made by Gilead Sciences Inc., combines tenofovir/emtricitabine (Truvada) with rilpivirine (Edurant), a Johnson & Johnson drug that received FDA approval in May. The combination treatment will cost approximately $1,705 a month.

A statement by Gilead said the approval of Complera was supported by data from two 48-week, Phase III studies -- ECHO and THRIVE -- that compared rilpivirine to efavirenz (Sustiva), made by Bristol-Myers Squibb Co., in treatment-naive adults with HIV-1 infection. Most patients in the rilpivirine study arm received Truvada as well.

Gilead stressed consideration of the following before starting patients on Complera:

Further, Complera has boxed warnings concerning lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.

For more information, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm.

Back to other news for August 2011

Excerpted from:
Reuters Health Medical News
08.10.2011




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/63485/us-food-and-drug-administration-approves-gileads-o.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.